AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the Alzheimer conference AD/PD 2023, which will be held in Gothenburg, Sweden, on March 28 – April 1.
The abstract, titled In vitro and in vivo profile of AC-0027875, a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease, will be presented at the international Alzheimer conference AD/PD 2023 by Dr. Johan Sandin, CSO at AlzeCure. The other co-authors are Gunnar Nordvall, Märta Dahlström, Lotta Agholme, Johan Lundkvist, Maria Backlund, Veronica Lidell, Azita Rasti, Sanja Juric, Magnus Halldin, Pontus Forsell and Henrik Zetterberg.
The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®. In the studies, the substance exhibits a high concentration in the brain which results in powerful effects on the production of the protein amyloid-beta, where the amount of toxic Aβ42 is reduced by over 50%. AlzeCure's GSM exhibits several key properties that make it suitable as a preventive or disease-modifying treatment for Alzheimer's disease.
“We affect the production of toxic Aβ42, the very building block of the amyloid plaques that are so characteristic of the disease. We also do it with a mechanism that has a strong genetic connection to the disease. Our data with AC-0027875 show AlzeCure's ability to produce new GSM substances with potent effects,” said Gunnar Nordvall, PhD, Director of Medicinal Chemistry at AlzeCure and project manager for Alzstatin.
"We see continued increasing interest for this mechanism in the Alzheimer's field, especially as the so-called amyloid hypothesis has received further clinical validation. We see exciting possibilities for Alzstatin both as an oral preventive treatment, but also as a disease-modifying maintenance treatment against Alzheimer's. These new data with AC-0027875 have been produced in collaboration with Professor Henrik Zetterberg's group at the University of Gothenburg and strengthen the continued development work and ongoing business discussions, said AlzeCure Pharma’s CEO Martin Jönsson.
The abstract and poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).
